Folic acid-functionalized PEGylated niosomes co-encapsulated cisplatin and doxoribicin exhibit enhanced anticancer efficacy
Abstract The medical field is faced with the difficult task of developing a new approach to curing cancer, which is prevalent in organs such as the breast and ovaries and has a high mortality rate. Since chemotherapy is the conventional method of treatment, efforts are being made to improve it to he...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-02-01
|
| Series: | Cancer Nanotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12645-024-00252-8 |
| _version_ | 1827328599856775168 |
|---|---|
| author | Mona Safari Sharafshadeh Farzaneh Tafvizi Parvin Khodarahmi Somayeh Ehtesham |
| author_facet | Mona Safari Sharafshadeh Farzaneh Tafvizi Parvin Khodarahmi Somayeh Ehtesham |
| author_sort | Mona Safari Sharafshadeh |
| collection | DOAJ |
| description | Abstract The medical field is faced with the difficult task of developing a new approach to curing cancer, which is prevalent in organs such as the breast and ovaries and has a high mortality rate. Since chemotherapy is the conventional method of treatment, efforts are being made to improve it to help patients function better. Fortunately, with the use of nanocarriers and their remarkable ability to manage and direct drug delivery, progress is being made in cancer treatment. In addition, folic acid-coated nanocarriers offer several advantages in drug delivery, including improved stability, bioavailability, targeted delivery and drug solubility. These properties make them promising tools for improving cancer treatment efficacy. This research focused on investigating the stability of a specific niosomal formulation (consisting of Span 60 and cholesterol) under different temperature conditions (4 and 25 ℃) for 2 months. In addition, the drug release rate of the formulation was evaluated. The results showed that the size and polydispersity index increased significantly in the stability studies, but the entrapment efficiency% decreased dramatically over time. In addition, encapsulation of drugs in niosomal formulations resulted in stable and slow drug release. The cytotoxicity evaluation results of formulations containing doxorubicin and cisplatin show their significant inhibitory effect on both breast and ovarian cancer cell lines (IC50 for DOX–CIS–Nio@PEG–FA formulation was 6.11 and 17.87 µg/mL for A2780 and MCF-7, respectively). Niosomes loaded with a combination of two drugs were found to affect gene expression in the cancer cell lines tested. They decreased the expression of BCl2, VEGF, CCND1, and HER2 genes while increasing the expression of BAX gene. Flow cytometry results indicated that niosomes loaded with doxorubicin and cisplatin increased the rate of apoptosis in both cell lines compared to a drug mixture. ROS and cell cycle arrest, confirm the significant inhibition of cancer cells and their destruction in the presence of the synthesized noisome formulation in comparison to free drugs and the combination of two drugs. The potential of this novel approach for delivering drugs to cancer cells lies in the ability to combine treatments and target multiple cancers simultaneously. Such formulations allow co-delivery of drugs to different cancer cells, thereby improving the efficacy of chemotherapy through synergistic effects between drugs. Graphical Abstract |
| first_indexed | 2024-03-07T15:19:53Z |
| format | Article |
| id | doaj.art-55acb2c37f1e413a8a4ae7a6040558ff |
| institution | Directory Open Access Journal |
| issn | 1868-6958 1868-6966 |
| language | English |
| last_indexed | 2024-03-07T15:19:53Z |
| publishDate | 2024-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Nanotechnology |
| spelling | doaj.art-55acb2c37f1e413a8a4ae7a6040558ff2024-03-05T17:41:22ZengBMCCancer Nanotechnology1868-69581868-69662024-02-0115112510.1186/s12645-024-00252-8Folic acid-functionalized PEGylated niosomes co-encapsulated cisplatin and doxoribicin exhibit enhanced anticancer efficacyMona Safari Sharafshadeh0Farzaneh Tafvizi1Parvin Khodarahmi2Somayeh Ehtesham3Department of Biology, Parand Branch, Islamic Azad UniversityDepartment of Biology, Parand Branch, Islamic Azad UniversityDepartment of Biology, Parand Branch, Islamic Azad UniversityDepartment of Biology, Parand Branch, Islamic Azad UniversityAbstract The medical field is faced with the difficult task of developing a new approach to curing cancer, which is prevalent in organs such as the breast and ovaries and has a high mortality rate. Since chemotherapy is the conventional method of treatment, efforts are being made to improve it to help patients function better. Fortunately, with the use of nanocarriers and their remarkable ability to manage and direct drug delivery, progress is being made in cancer treatment. In addition, folic acid-coated nanocarriers offer several advantages in drug delivery, including improved stability, bioavailability, targeted delivery and drug solubility. These properties make them promising tools for improving cancer treatment efficacy. This research focused on investigating the stability of a specific niosomal formulation (consisting of Span 60 and cholesterol) under different temperature conditions (4 and 25 ℃) for 2 months. In addition, the drug release rate of the formulation was evaluated. The results showed that the size and polydispersity index increased significantly in the stability studies, but the entrapment efficiency% decreased dramatically over time. In addition, encapsulation of drugs in niosomal formulations resulted in stable and slow drug release. The cytotoxicity evaluation results of formulations containing doxorubicin and cisplatin show their significant inhibitory effect on both breast and ovarian cancer cell lines (IC50 for DOX–CIS–Nio@PEG–FA formulation was 6.11 and 17.87 µg/mL for A2780 and MCF-7, respectively). Niosomes loaded with a combination of two drugs were found to affect gene expression in the cancer cell lines tested. They decreased the expression of BCl2, VEGF, CCND1, and HER2 genes while increasing the expression of BAX gene. Flow cytometry results indicated that niosomes loaded with doxorubicin and cisplatin increased the rate of apoptosis in both cell lines compared to a drug mixture. ROS and cell cycle arrest, confirm the significant inhibition of cancer cells and their destruction in the presence of the synthesized noisome formulation in comparison to free drugs and the combination of two drugs. The potential of this novel approach for delivering drugs to cancer cells lies in the ability to combine treatments and target multiple cancers simultaneously. Such formulations allow co-delivery of drugs to different cancer cells, thereby improving the efficacy of chemotherapy through synergistic effects between drugs. Graphical Abstracthttps://doi.org/10.1186/s12645-024-00252-8ApoptosisBreast cancerCisplatin/doxorubicin co-deliveryFolic acid-functionalized pegylated niosomeOvarian cancer |
| spellingShingle | Mona Safari Sharafshadeh Farzaneh Tafvizi Parvin Khodarahmi Somayeh Ehtesham Folic acid-functionalized PEGylated niosomes co-encapsulated cisplatin and doxoribicin exhibit enhanced anticancer efficacy Cancer Nanotechnology Apoptosis Breast cancer Cisplatin/doxorubicin co-delivery Folic acid-functionalized pegylated niosome Ovarian cancer |
| title | Folic acid-functionalized PEGylated niosomes co-encapsulated cisplatin and doxoribicin exhibit enhanced anticancer efficacy |
| title_full | Folic acid-functionalized PEGylated niosomes co-encapsulated cisplatin and doxoribicin exhibit enhanced anticancer efficacy |
| title_fullStr | Folic acid-functionalized PEGylated niosomes co-encapsulated cisplatin and doxoribicin exhibit enhanced anticancer efficacy |
| title_full_unstemmed | Folic acid-functionalized PEGylated niosomes co-encapsulated cisplatin and doxoribicin exhibit enhanced anticancer efficacy |
| title_short | Folic acid-functionalized PEGylated niosomes co-encapsulated cisplatin and doxoribicin exhibit enhanced anticancer efficacy |
| title_sort | folic acid functionalized pegylated niosomes co encapsulated cisplatin and doxoribicin exhibit enhanced anticancer efficacy |
| topic | Apoptosis Breast cancer Cisplatin/doxorubicin co-delivery Folic acid-functionalized pegylated niosome Ovarian cancer |
| url | https://doi.org/10.1186/s12645-024-00252-8 |
| work_keys_str_mv | AT monasafarisharafshadeh folicacidfunctionalizedpegylatedniosomescoencapsulatedcisplatinanddoxoribicinexhibitenhancedanticancerefficacy AT farzanehtafvizi folicacidfunctionalizedpegylatedniosomescoencapsulatedcisplatinanddoxoribicinexhibitenhancedanticancerefficacy AT parvinkhodarahmi folicacidfunctionalizedpegylatedniosomescoencapsulatedcisplatinanddoxoribicinexhibitenhancedanticancerefficacy AT somayehehtesham folicacidfunctionalizedpegylatedniosomescoencapsulatedcisplatinanddoxoribicinexhibitenhancedanticancerefficacy |